Key takeaways
- GSM affects most postmenopausal women and is progressive — unlike hot flushes, it does not resolve with time.
- Restoring epithelial glycogen lets lactobacilli return and pH fall, which is the mechanism behind the drop in recurrent UTIs.
- Systemic exposure is roughly a hundredth of systemic hormone therapy, so those safety concerns do not transfer.
- Oncology guidance supports it for many breast cancer survivors with severe symptoms, as a shared decision.
- Relief at four to eight weeks, full effect by three months, and treatment continues because the deficiency does.
There is a treatment that resolves painful sex, urinary urgency, vaginal dryness and recurrent urinary tract infections in postmenopausal women, works by reversing the tissue change causing them rather than masking symptoms, and delivers almost nothing into the bloodstream. It is decades old, inexpensive, and available in four forms. Most women who need it have never heard of it, and a good number who have heard of it were told it was unsafe on the basis of evidence about an entirely different treatment.
What GSM actually is
Genitourinary syndrome of menopause — the current name for what was called atrophic vaginitis — is the cluster of changes that follows estrogen withdrawal in vulvovaginal, urethral and bladder trigone tissue. All of those tissues are estrogen-dependent; they share an embryological origin, which is why they change together:
- Vaginal dryness, itching and burning
- Pain with intercourse, ranging from friction to tearing
- Urinary urgency and frequency
- Recurrent urinary tract infections
- Stress incontinence
- Symptoms attributed to mild prolapse
- Reduced libido, partly mechanical and partly anticipatory
It affects a majority of postmenopausal women and, unlike hot flushes, it does not resolve with time (Nappi et al., Climacteric 2016). That single distinction is the most important thing on this page. Vasomotor symptoms peak and fade. GSM is progressive: untreated, it is worse at 70 than at 60. Waiting it out is the one strategy guaranteed not to work.
It is also chronically under-reported. Women do not raise it, and clinicians do not ask, so a condition affecting the majority of a population gets treated in a minority of it. The symptoms are frequently attributed to ageing in general, to a relationship, or to recurrent infection — which is how a woman ends up on her fourth course of antibiotics in a year for a problem that is not primarily infective.
How it works locally
Vaginal and urethral epithelium is dense in estrogen receptors. Withdrawal thins the epithelium, reduces blood flow, reduces glycogen content in the surface cells, and lets pH rise. Local estradiol reverses each of those steps.
The pH change deserves its own explanation, because it is the mechanism most people have never had described. Estrogenised epithelium is rich in glycogen. Lactobacilli metabolise that glycogen and produce lactic acid, keeping vaginal pH acidic — around 4. That acidity suppresses colonisation by the coliform organisms that cause urinary tract infections. When estrogen falls, glycogen falls, lactobacilli decline, pH rises toward neutral, and the environment stops excluding the organisms it used to exclude.
Local estradiol restores epithelial thickness, elasticity and vascular tone, restores glycogen, and lets the lactobacilli population and the acidic pH re-establish (Lethaby et al., Cochrane Database Syst Rev 2016). This is anatomical reversal, not symptom suppression, which is why the effect builds over weeks rather than arriving in an hour — and why recurrent UTI frequency falls as a downstream consequence rather than as a separate treatment.
Why the safety profile is different
Properly dosed local vaginal estrogen produces serum estradiol concentrations essentially indistinguishable from untreated postmenopausal baseline. Systemic exposure is on the order of a hundredth of typical systemic hormone therapy (Santen et al., Menopause 2020).
That number is the whole argument. Concerns attached to systemic hormone therapy — clotting risk, the breast and cardiovascular questions, the timing-window debate — are dose-and-exposure arguments. At a hundredth of the exposure, they do not transfer. Local vaginal estrogen is not a low dose of systemic therapy; it is a topical treatment for a tissue that happens to respond to a hormone.
There is one practical caveat worth stating honestly: absorption is highest in the first weeks, when the epithelium is thin and permeable, and falls as the tissue thickens. This is one reason regimens start with a loading phase and then step down — and it is also why using more than prescribed does not make it work faster.
Breast cancer survivors
This is where the treatment is most needed and least given. Severe GSM is common in women on aromatase inhibitors, because those medications drive estradiol to the floor by design, and the resulting symptoms are frequently a reason women stop taking a drug that is preventing recurrence.
Current oncology guidance supports local vaginal estrogen for many breast cancer survivors with severe GSM, particularly where non-hormonal options — moisturisers, lubricants, pelvic floor physiotherapy — have been tried and failed (Carter et al., J Clin Oncol 2018). It is a shared decision with the treating oncologist, and it is no longer the absolute contraindication it was treated as for years. The caution is greatest in women on aromatase inhibitors specifically, where even minimal absorption is worth discussing, and the discussion should happen rather than being pre-empted by an assumption.
The options, and how to choose between them
| Form | How it is used | Suits |
|---|---|---|
| Estradiol cream | Applied intravaginally and to the vulva; dose is adjustable | Vulvar and introital symptoms, where you need to treat tissue you can reach with a finger |
| Vaginal tablet (Vagifem, Yuvafem) | Inserted twice weekly after a loading phase | Anyone who finds cream messy; clean and dose-controlled |
| Vaginal ring (Estring) | Inserted and replaced every 90 days | Adherence — four actions a year, nothing to remember |
| DHEA insert (Intrarosa) | Converted to estrogen and androgen within the cell | Women who prefer to avoid an estrogen product outright |
| Compounded cream | Dose customised through a 503A pharmacy | Sensitivity to a commercial vehicle, or a dose outside standard strengths |
Efficacy across these is broadly comparable, so the choice is a practical one. Cream reaches the vulva, which tablets and rings do not; if pain is at the entrance rather than deeper, that matters. The ring wins on adherence, which is the variable that actually determines outcome in a lifelong treatment.
Timeline, and the part people get wrong
- Weeks 1-2. Tissue begins rehydrating. Some relief of dryness and irritation. Not much else yet.
- Weeks 4-8. The substantial change: dryness, pain with intercourse and urinary urgency all improve meaningfully. This is where most women decide whether it worked, which is roughly the right time to judge it.
- Month 3 and beyond. Full epithelial restoration. UTI frequency falls, which lags the comfort improvement because it depends on the microbiome re-establishing rather than just the tissue thickening.
The part people get wrong is stopping. This treats an ongoing deficiency, so the tissue re-atrophies when it is withdrawn and symptoms return over some months. Continued use is appropriate and expected — the same way you would not stop a moisturiser and expect the effect to persist. The most common reason for treatment failure is a woman deciding she is better and stopping, then concluding when symptoms return that it did not work.
It also pairs well with the things that address the mechanical side: pelvic floor function is estrogen-dependent too, and strength training loads the whole system rather than one tissue.
The clinical pearl: a postmenopausal woman with recurrent UTIs is usually being managed as an infection problem when she has a tissue problem. Repeated antibiotics treat each episode and do nothing to the pH and epithelium that make the next one likely. Local estrogen changes the environment the infections keep arising in.
Bottom line
Local vaginal estrogen restores the tissue that estrogen withdrawal thinned, and with it the acidic pH that keeps urinary pathogens out. Systemic exposure is roughly a hundredth of systemic hormone therapy, which is why the safety concerns attached to that treatment do not transfer, and why it is appropriate for many women — including many breast cancer survivors, in discussion with their oncologist — who cannot use systemic hormones. Meaningful relief arrives in four to eight weeks, full effect by three months, and treatment is ongoing because the underlying deficiency is. Its underuse is a communication failure, not a clinical one. Discuss it with a physician if any of the symptoms above are familiar; the 60-second assessment is one route to that conversation.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
